Niagen Reports Q3 2026 Net Loss Amid Declining Sales and Increased Competition
Niagen (NAGE) reported a challenging third quarter for 2026, characterized by a 20% year-over-year decline in net sales to $27.2 million. The company swung from a net income of $4.6 million in the prior year's quarter to a net loss of $1.2 million, or $0.01 per diluted share. This downturn was driven by increased market competition in the ingredient sector and higher operating expenses related to brand awareness campaigns and patent litigation. Despite the top-line contraction, Niagen saw 13% year-over-year growth in direct-to-consumer website sales. The company maintains a strong liquidity position with $69.5 million in cash and no outstanding debt. Management expects sequential revenue improvement in Q4 and is focusing on retail expansion through GNC and Sam's Club, alongside significant clinical research efforts to bolster long-term brand value.
Tickers: $CDXC
Topics: Adjusted EBITDA Direct-to-Consumer Growth Gross Margin Net Loss Net Sales
Read the full article at Motley Fool
Part of the story Niagen Reports Q3 2026 Net Loss Amid Declining Sales and Increased Competition (8 articles)